Andrew Hall is the CEO of Consano Bio, an early-stage biotech company based in Greater Boston that is developing a first-in-class therapeutic approach.
Andrew Hall is the CEO of Consano Bio, an early-stage biotech company based in Greater Boston that is developing a first-in-class therapeutic approach for repairing damaged nerves. Prior to Consano Bio, he was CEO of IMV Inc., a clinical-stage biopharmaceutical company focused on oncology, and previously served as its CBO and an executive board member. He also spent seven years at Celgene, leading corporate development and pipeline strategy for immunology, and over 15 years in leadership roles at Merck, BMS, and Schering Plough.
Full founder directory · Investor directory · Company funding database · Fundraising library